Hélène-Marie Lanoiselée,Gaël Nicolas,David Wallon,Anne Rovelet-Lecrux,Morgane Lacour,Stéphane Rousseau,Anne-Claire Richard,Florence Pasquier,Adeline Rollin-Sillaire,Olivier Martinaud,Muriel Quillard-Muraine,Vincent de la Sayette,Claire Boutoleau-Bretonniere,Frédérique Etcharry-Bouyx,Valérie Chauviré,Marie Sarazin,Isabelle le Ber,Stéphane Epelbaum,Thérèse Jonveaux,Olivier Rouaud,Mathieu Ceccaldi,Olivier Félician,Olivier Godefroy,Maite Formaglio,Bernard Croisile,Sophie Auriacombe,Ludivine Chamard,Jean-Louis Vincent,Mathilde Sauvée,Cecilia Marelli-Tosi,Audrey Gabelle,Canan Ozsancak,Jérémie Pariente,Claire Paquet,Didier Hannequin,Dominique Campion,,

Abstract:BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series.METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification.CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

Identification of the Third Case of PSEN1 Tyr389His Variant in Early-Onset Alzheimer’s Disease in Korea

Identification of PSEN1 and APP Gene Mutations in Korean Patients with Early-Onset Alzheimer's Disease

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease

Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease

The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family

Identification of a Novel PSEN1 Gly111Val Missense Mutation in a Chinese Pedigree with Early-Onset Alzheimer's Disease

A Novel Rare PSEN2 Val226Ala in PSEN2 in a Korean Patient with Atypical Alzheimer's Disease, and the Importance of PSEN2 5th Transmembrane Domain (TM5) in AD Pathogenesis

P3‐120: MOLECULAR GENETIC ANALYSIS OF APP, PSEN1, AND PSEN2 GENES IN CHINESE PATIENTS WITH ALZHEIMER'S DISEASE

Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing

Identification of a Rare <i>PSEN1</i> Mutation (Thr119Ile) in Late-Onset Alzheimer's Disease With Early Presentation of Behavioral Disturbance

Clinical and Genetic Analysis of Early-Onset Alzheimer's Disease in Two Chinese Han Families with Presenilin-1 Mutations

Screening and Functional Validations of APP, PSEN1 and PSEN2 Mutations from PUMCH Dementia Cohort

Identification of PSEN1 Mutations P.m233l and P.r352c in Han Chinese Families with Early-Onset Familial Alzheimer's Disease.

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Very Early-Onset Alzheimer’s Disease in the Third Decade of Life with De Novo PSEN1 Mutations

Two Novel Mutations and a De Novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Case report: Double mutations in a patient with early-onset Alzheimer's disease in China, PSEN2 and IDE variants

A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Aβ42/Aβ40 Ratio.

The Associations of APP, PSEN1, and PSEN2 Genes with Alzheimer's Disease: A Large Case-Control Study in Chinese Population